Skip to the main content
LongevityGLP1
Compound

Ozempic: what it is, what it's approved for, and what it costs

Marisol Keane

How this page is paid for: Some links here are partner links. If you start care through one, the provider may pay LongevityGLP1 a fee, and your monthly price stays the same. How we make money

The short answer

Ozempic is a weekly semaglutide injection from Novo Nordisk, approved for adults with type 2 diabetes to lower blood sugar and reduce heart and kidney risks. It is not FDA-approved for weight loss, although people lose weight on it; Wegovy is the same drug approved for weight management. A prescription is required.

Definition

Ozempic is a once-weekly semaglutide injection made by Novo Nordisk. FDA approved it in 2017 for adults with type 2 diabetes. It is not approved for weight loss; the weight-loss version of semaglutide is Wegovy.

Key facts

Key facts: Ozempic
FactDetail
Active ingredientSemaglutide, a GLP-1 receptor agonist
MakerNovo Nordisk
First FDA approvalDecember 5, 2017 (NDA 209637)[3]
Approved forType 2 diabetes in adults: blood sugar control; lower heart-event risk with heart disease; slow kidney decline with chronic kidney disease[1]
Not approved forWeight loss; that label belongs to Wegovy
FormWeekly injection: multi-dose pens (0.25/0.5 mg, 1 mg, 2 mg doses) and single-dose prefilled syringes (0.25, 0.5, 1 mg)
Boxed warningThyroid C-cell tumors in rodents
Self-pay (NovoCare)$349 a month (0.25 to 1 mg), $499 (2 mg); $199 intro for new patients[9]
PrescriptionRequired

Ozempic is a diabetes drug that became a household name for weight loss. The ingredient, semaglutide, does both jobs. The label doesn't. Ozempic's label covers type 2 diabetes only, and the weight-loss label belongs to a sister product, Wegovy. Once you hold onto that difference, most Ozempic questions answer themselves.

Ozempic is semaglutide, sold for type 2 diabetes

Ozempic is the brand name for weekly semaglutide injections that Novo Nordisk sells for adults with type 2 diabetes. It arrived in December 2017 [3]. Since then the same company has launched three more semaglutide products under other names, each with its own label.

That matters because the name on the box decides who the drug is approved for, which doses come in the pen, and what insurance will pay for. Ozempic's box says diabetes. If you've seen it called a weight-loss shot, that's off-label use, and we'll get to what it means below.

The quick answer to “who makes Ozempic?” is Novo Nordisk, and only Novo Nordisk. Telehealth companies, pharmacies and clinics can prescribe or dispense it. None of them makes it, and a product sold under another name isn't Ozempic.

Ozempic is approved for three uses, all in type 2 diabetes

The Ozempic label lists three uses, all in adults with type 2 diabetes. It lowers blood sugar alongside diet and exercise. It cuts the risk of heart attack, stroke and cardiovascular death in people who already have heart disease. And it slows kidney decline in people with chronic kidney disease [1].

Ozempic's approved uses (label, June 2026)
UseWho it's forTrial behind itApproved
Blood sugar controlAdults with type 2 diabetes, with diet and exerciseSUSTAIN glycemic trialsDecember 5, 2017 [3]
Lower risk of heart attack, stroke and cardiovascular deathAdults with type 2 diabetes and established heart diseaseSUSTAIN-6 [10]January 16, 2020 [4]
Slow kidney decline, kidney failure and cardiovascular deathAdults with type 2 diabetes and chronic kidney diseaseFLOW [11]January 28, 2025 [5]
Weight lossNot approvedNone for Ozempic; Wegovy carries the weight labelWegovy approved June 4, 2021 [6]

Approval dates from FDA approval letters and Drugs@FDA. The kidney use rests on FLOW, which tested the 1 mg dose.

What is Ozempic used for in practice? Mostly what the table says: blood sugar first, with the heart and kidney benefits as reasons a prescriber might choose it over another diabetes drug. Doctors also prescribe it off-label for weight in people without diabetes. That's legal for a licensed prescriber, but it means FDA hasn't reviewed Ozempic for that job, and insurers often won't pay for it.

Ozempic works by copying a gut hormone called GLP-1

Ozempic mimics GLP-1, a hormone your gut releases after a meal. The label says semaglutide raises insulin and lowers glucagon “in a glucose-dependent manner,” so it works harder when blood sugar is high, and it causes “a minor delay in gastric emptying” after meals [1]. The label also notes that semaglutide reduces body weight.

Does Ozempic burn fat, or does it just curb appetite? The labels describe appetite and calorie intake, not a fat-burning action. Wegovy's label, written for the same molecule, says semaglutide “decreases calorie intake” and that “the effects are likely mediated by affecting appetite” [2]. People lose weight because they eat less. The full molecule story, including how semaglutide reaches the brain's appetite centers, is on our semaglutide page.

Ozempic is not approved for weight loss; Wegovy is

Ozempic is not approved for weight loss. Prescribing it for that is off-label, and Wegovy is the semaglutide product approved for weight management. The two contain the same ingredient, but they come in different pens and doses. Wegovy's highest regular dose, 2.4 mg, is above Ozempic's 2 mg ceiling.

So why do people lose weight on Ozempic? Because semaglutide reduces appetite at diabetes doses too. In the SURPASS-2 trial, people with type 2 diabetes on semaglutide 1 mg lost weight over 40 weeks, though less than those on tirzepatide [12]. The weight effect is real. It just isn't what Ozempic's label is for. Our Ozempic vs Wegovy comparison lays out the doses, labels and coverage side by side.

The trials showed fewer heart events and slower kidney decline

In type 2 diabetes at high cardiovascular risk, weekly semaglutide lowered major cardiovascular events from 8.9% to 6.6% over two years, but it raised diabetic eye complications (SUSTAIN-6) [10]. In type 2 diabetes with kidney disease, semaglutide 1 mg cut major kidney events by 24% (FLOW) [11].

Major cardiovascular events over about two years, SUSTAIN-6
Semaglutide
6.6%[10]
Placebo
8.9%[10]
Key Ozempic trials and what they found
TrialWho was studiedResultFunded by
SUSTAIN-6 [10]3,297 adults with type 2 diabetes at high heart risk, 104 weeksHeart events 6.6% vs 8.9% (hazard ratio 0.74); eye complications hazard ratio 1.76Novo Nordisk
FLOW [11]3,533 adults with type 2 diabetes and kidney disease, median 3.4 yearsMajor kidney events hazard ratio 0.76; stopped early for benefitNovo Nordisk
SURPASS-2 [12]1,879 adults with type 2 diabetes on metformin, 40 weeksA1C fell 1.86 points on semaglutide 1 mg vs 2.01 to 2.30 on tirzepatideEli Lilly

A hazard ratio below 1 means fewer events on the drug. SURPASS-2 was run by the maker of tirzepatide, the comparison drug.

Is Ozempic better than insulin? No trial in this table answers that. Ozempic and insulin work differently, and many people with type 2 diabetes use both. A prescriber chooses by A1C, weight, heart and kidney risk, and the risk of low blood sugar. That's a conversation, not a ranking.

One honest caveat: the eye signal in SUSTAIN-6 is why the label carries a warning about diabetic retinopathy. If you have eye disease from diabetes, your prescriber will want to watch it closely.

Most side effects are stomach-related, and the label has a boxed warning

The most common Ozempic side effects are gastrointestinal. The label lists nausea, vomiting, diarrhea, abdominal pain and constipation as the reactions seen in at least 5% of people [1]. In the placebo-controlled trials, nausea hit 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo.

Common Ozempic side effects in placebo-controlled trials (label Table 1)
Side effectPlaceboOzempic 0.5 mgOzempic 1 mg
Nausea6.1%15.8%20.3%
Vomiting2.3%5%9.2%
Diarrhea1.9%8.5%8.8%
Abdominal pain4.6%7.3%5.7%
Constipation1.5%5%3.1%

From the Ozempic label's pool of two placebo-controlled trials in type 2 diabetes. Most nausea, vomiting and diarrhea happened while the dose was being raised.

Stomach side effects led 3.1% of people on 0.5 mg and 3.8% on 1 mg to stop, against 0.4% on placebo [1]. The label also warns about pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar when combined with insulin or sulfonylureas, allergic reactions and aspiration during anesthesia.

The boxed warning is about thyroid C-cell tumors in rodents. The label says it's unknown whether Ozempic causes them in people, and it rules the drug out if you or a family member has had medullary thyroid carcinoma or MEN 2. For a fuller list, see Ozempic safety and side effects, the stomach-specific guide on nausea, diarrhea and constipation, and our explainer on “Ozempic face”.

Ozempic is a once-weekly injection, and the label sets the dose range

The label starts Ozempic at 0.25 mg once a week and allows up to 2 mg a week; your prescriber sets the steps in between [1]. It's taken once weekly, on the same day each week, with or without food.

Is Ozempic a pill or a shot? Ozempic is a shot. It comes in multi-dose pens and in single-dose prefilled syringes. There is also a daily tablet called “Ozempic tablets,” but it's a separate product: FDA approved renaming a newer Rybelsus formulation to that name on January 30, 2026 [7]. The tablets treat type 2 diabetes too, with different doses. Our guide to oral semaglutide covers the pills.

What does microdosing Ozempic mean? It's taking doses below the label's starting dose or keeping someone on a tiny dose long term. No trial has tested that, and it isn't on the label. Our GLP-1 microdosing guide explains what is and isn't known.

Ozempic, Wegovy, the pills and compounded semaglutide share one molecule

Several products contain semaglutide, and only their labels, not the molecule, decide what each one is for. Here's where Ozempic sits among them.

Semaglutide products compared with Ozempic
ProductFormApproved forHow it relates to Ozempic
OzempicWeekly injectionType 2 diabetes (blood sugar, heart, kidney)This page
WegovyWeekly injection or daily tabletWeight management, heart-risk reduction, MASHSame molecule, weight label, higher top dose
Ozempic tablets and RybelsusDaily tabletType 2 diabetesSame molecule by mouth; oral semaglutide guide
Compounded semaglutidePharmacy-made injection and other formsNot FDA-approvedNot Ozempic; see compounded vs Ozempic

Compounded semaglutide deserves one plain sentence: it isn't FDA-approved, FDA doesn't review it for safety or effectiveness, and FDA doesn't check its quality before it ships [8]. FDA also warns that counterfeit Ozempic has been sold in the US [8]. Buy it only through a licensed pharmacy with a prescription.

Comparing Ozempic with other diabetes and weight drugs? See Ozempic vs Mounjaro, Ozempic vs Zepbound and metformin vs Ozempic.

Self-pay Ozempic costs $349 to $499 a month through NovoCare

Ozempic's self-pay price through NovoCare Pharmacy is $349 a month for the 0.25, 0.5 or 1 mg pens and $499 a month for 2 mg [9]. New patients pay $199 a month for their first two fills of 0.25 or 0.5 mg, through December 31, 2026. One month means one pen.

What Ozempic costs from the maker (NovoCare)
OptionWho it's forPriceFine print
Self-pay intro offerNew patients, 0.25 or 0.5 mg$199 a monthTwo monthly fills through December 31, 2026
Self-pay pen0.25, 0.5 or 1 mg$349 a monthOne month = 1 pen
Self-pay pen2 mg$499 a monthOne month = 1 pen
Ozempic pill (tablets)Self-pay, 1.5 mgFrom $149 a monthHigher tablet doses are listed in NovoCare's pricing table
Savings cardCommercial insurance that covers OzempicAs little as $25 a monthUp to $100 a month in savings; government plans excluded

Source: NovoCare's Ozempic savings page. NovoCare says pricing will be updated after December 31, 2026.

Insurance is the bigger lever. Coverage usually depends on a type 2 diabetes diagnosis, because that's what the label covers. Our guides to Ozempic's cost without insurance and Medicare coverage for Ozempic go deeper, and the monthly cost calculator turns a plan's billing into a real monthly figure.

You need a prescription, from your own clinician or a telehealth program

Ozempic needs a prescription from a licensed clinician. Your own doctor can send it to any pharmacy or to NovoCare Pharmacy. Telehealth programs that prescribe brand GLP-1 drugs may write it too, usually after an online intake and a video or message visit.

Is a telehealth brand the same as Ozempic? No. A telehealth company is a care service; it doesn't make the drug. If a program prescribes real Ozempic, the pen comes from Novo Nordisk through a licensed pharmacy. If it sells something else under its own name, that product is not Ozempic.

Telehealth programs that list brand Ozempic
ProviderWhat the monthly price coversMonthly cost
GalaPartnerMedication, provider visit and shipping$1,299/mo

Prices from each provider's own site and shown as a calendar-month cost. Several programs list Ozempic inside weight-loss plans; Ozempic's label is type 2 diabetes, so that use is off-label.

Also offered by (no standing monthly price published): Sesame, altRx, Wellmedr.

Notice the spread. Some programs pass through the maker's self-pay price and add a fee. Others charge a single cash price far above it. Before you pay, ask what's included and whether the pen comes from a named pharmacy. For a broader look at how these services work, read how GLP-1 telehealth works.

Research on Ozempic

Ozempic compared

Compare providers

Providers that offer Ozempic

  • Maximus

    You want a brand GLP-1 pill such as Foundayo or Wegovy tablets at a printed cash price, from a provider that names its pharmacies.

    Maximus review →
  • Ro

    You want an FDA-approved GLP-1, such as the Wegovy pill, Foundayo or Zepbound, at a published cash price for each dose, or help getting a pen covered by insurance.

    Ro review →
  • Heally

    You want to talk through off-label rapamycin or metformin with a physician in a live visit, with the medication and visit bundled at a printed monthly price.

    Heally review →
  • MEDGmPartner

    You want labs, clinician visits, side-effect medicine and shipping in one monthly price that holds at every dose, from a program that names its pharmacies.

    MEDGm review →Visit site →
  • WePeptideRx

    You want to see exactly what each dose of compounded tirzepatide or semaglutide will cost before you start, with the visit and shipping included.

    WePeptideRx review →

See all 21 providers on the brand Wegovy and Zepbound lineup →

Frequently asked

Is Ozempic for weight loss?
No. Ozempic is FDA-approved for type 2 diabetes. People often lose weight on it, but prescribing it for weight alone is off-label. Wegovy is the semaglutide product approved for weight management.
Is Ozempic a pill or a shot?
Ozempic is a once-weekly shot. A separate daily tablet called Ozempic tablets (formerly a Rybelsus formulation) also treats type 2 diabetes, with different doses. The two aren't swapped mg for mg.
Does Ozempic burn fat or just suppress appetite?
The labels describe reduced appetite and calorie intake, not a direct fat-burning action. Semaglutide also slows stomach emptying after meals. People lose weight mainly because they eat less.
Is Ozempic insulin?
No. Ozempic is a GLP-1 receptor agonist, not insulin. It raises your own insulin release when blood sugar is high. Some people use both, and the label warns that combining them raises the risk of low blood sugar.
What does microdosing Ozempic mean?
It means taking doses below the label's starting dose, or staying on a very small dose. No trial has tested it, and the label doesn't include it. Ask your prescriber before changing any dose.
Do you need a prescription for Ozempic?
Yes. Ozempic is prescription-only in the US. A licensed clinician, in person or through telehealth, has to prescribe it, and a licensed pharmacy dispenses it.

Sources

  1. [1] Ozempic (semaglutide) injection, prescribing information (2026). DailyMed label
  2. [2] Wegovy (semaglutide) injection and tablets, prescribing information (2026). DailyMed label
  3. [3] Drugs@FDA: Ozempic, NDA 209637 (2026). FDA
  4. [4] Ozempic supplement approval letter S-003 (cardiovascular indication) (2020). FDA
  5. [5] Ozempic supplement approval letter S-025 (kidney indication) (2025). FDA
  6. [6] Wegovy approval letter, NDA 215256 (2021). FDA
  7. [7] NDA 213051 S-030 approval letter (Ozempic tablets name) (2026). FDA
  8. [8] FDA's concerns with unapproved GLP-1 drugs used for weight loss (2026). FDA
  9. [9] NovoCare: Ozempic savings offer and self-pay pricing (2026). Company website
  10. [10] Marso SP. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016). PMID 27633186
  11. [11] Perkovic V. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (2024). PMID 38785209
  12. [12] Frías JP. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021). PMID 34170647